Alzheimer’s Disease in Primary Care: Gaining Diagnostic and Management Confidence
It is important to recognize and address cognitive complaints and dementia symptoms early in the disease continuum and as part of routine care. Steps to diagnose mild cognitive impairment and Alzheimer’s disease will be discussed, as will the importance of early treatment. Approaches to Alzheimer’s disease prevention, including lifestyle changes, will be presented, along with emerging disease-modifying therapies.
Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on 11/12/2020, and they are subject to change as new information is published.
Learning Objectives
Outline how to perform a cognitive assessment in all eligible patients
Select the appropriate pharmacologic treatment in patients with Alzheimer’s disease to slow symptomatic decline and monitor over time
Identify emerging therapies for Alzheimer’s disease
Describe the support services available to patients and caregivers as part of a comprehensive care plan
Additional Information
Liana G. Apostolova, MD, MSc, FAAN
Barbara and Peer Baekgaard Professor in Alzheimer's Disease Research
Professor in Neurology, Radiology, Medical and Molecular Genetics
Indiana Alzheimer Disease Center
Indiana University School of Medicine
Indianapolis, Indiana
Gad A. Marshall, MD
Associate Professor of Neurology
Harvard Medical School
Associate Medical Director of Clinical Trials
Center for Alzheimer Research & Treatment
Brigham and Women's Hospital
Massachusetts General Hospital
Boston, Massachusetts
Disclosures
The following financial relationships have been disclosed by faculty.
Liana G. Apostolova, MD, MSc, FAAN: Advisory Board for Biogen, Two Labs, IQVIA; Contracted Research for NIA, Roche Diagnostics, Alzheimer's Association, Life Molecular Imaging, AVID Radiophamaceuticals, Ownership Interest in Semiring, Inc.
Gad A. Marshall, MD: Contracted research for Eisai Inc., Eli Lilly and Company, Janssen Alzheimer Immunotherapy, Novartis, and Genentech. Consultant for Pfizer, Eisai, and Grifols Shared Services North America, Inc.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
AMA PRA Category 1 Credits™
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement
Pri-Med Institute designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number 040308.
Designation Statement
This program has been approved for 1.00 contact hour of continuing education, which includes 0.67 hour of pharmacology.
Instructions for Obtaining Credit
Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 2 out of the 2 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen.
Available Credit
- 1.00 AANP Contact Hours
- 0.67 AANP Pharmacology Contact Hours
- 1.00 AAPA Category I CME
- 1.00 MOC
- 1.00 AMA PRA Category 1 Credit™
This course is offered through Pri-Med.
To take this course you will be redirected to Pri-Med's website. You must login or create an account with Pri-Med in order to complete this activity.
Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch!